Dual-target or combination constructs: A 2024 CD44-targeted HA/Cisplatin nanogel displayed potent synergy in NSCLC, highlighting the clinical momentum for CD44-driven platinum therapy [29]. Here, CD44 is linked to non-small cell lung carcinoma.